Travere Therapeutics, Inc. (TVTX) — Stock Score Summary

Travere Therapeutics, Inc. (TVTX) has a MoatMap StockRank of 52/100 based on Quality (38/100), Value (18/100), and Momentum (83/100) factor scores. The current signal is HOLD. Travere Therapeutics is a biopharmaceutical company focused on rare kidney diseases. It does not align with our high-conviction macro themes and lacks the high ROIC and asset-light characteristics of a Terry Smith quality compounder, while also facing high clinical and regulatory binary risks.

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering life-changing therapies for people living with rare kidney and metabolic diseases. The company's primary commercial product, Filspari (sparsentan), is approved for reducing proteinuria in adults with primary IgA nephropathy. Travere's competitive position is secured by its specialized orphan drug pipeline, strong patient advocacy relationships, and targeted commercial execution.

Key Financial Metrics

Price$48.57
Market Cap$4.4B
P/E (Forward)9.37
Price/Book43.24
Return on Equity-69.4%
Return on Invested Capital-8.7%
Debt/Equity331.88
Gross Margin55.9%
Operating Margin-29.0%
Revenue Growth55.6%
Free Cash Flow$-51M

Travere Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Travere Therapeutics, Inc.’s (TVTX) StockRank?
MoatMap’s StockRank for Travere Therapeutics, Inc. (TVTX) is 52/100, with a Hold signal. It is a composite of Quality (38), Value (18), and Momentum (83) factor ranks across MoatMap’s 19,000+ stock universe.
Does Travere Therapeutics, Inc. have an economic moat?
Travere Therapeutics, Inc. (TVTX) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Travere Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Travere Therapeutics, Inc. (TVTX) is Hold, based on a StockRank of 52/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Travere Therapeutics, Inc. in?
Travere Therapeutics, Inc. (TVTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksTVTX deep dive reportAI ChampionsHow we score stocksSense-check another stock